The year 2015 for the Pharma and Biotech industry can be summarized in just three phrases: Pfallergan, Clinton’s Tweet, and CRISPR-Cas9. Reviewing what was an exceptional year, the IMAP report offers insights into merger mania, price pressure in the U.S., and accelerating innovation, which without a doubt moved the industry.

In this year’s edition of IMAP’s Pharma and Biotech, writers analyze last year’s deal flow in the industry, regional trends, and genomics. My Gene Counsel’s CEO Ellen Matloff comments on consumer genomics in a changing environment and the importance of digital tools moving forward.

To read the full report, click here.